2021 Year in Review - Renal-Cell Carcinoma

In a phase 2 study, sapanisertib did not improve outcomes in renal-cell carcinoma.
In a retrospective study, active therapy conferred a survival benefit versus BSC for patients who have disease progression on both nivolumab and cabozantinib.
Since the approval of dual immune checkpoint inhibition, real-world treatment patterns have evolved.
Blood flow measured by dynamic contrast-enhanced computed tomography can predict survival with antiangiogenic treatment.
The Meet-URO score combines inflammatory and clinical markers to predict response to nivolumab.
In a retrospective study, lenvatinib with or without everolimus resulted in antitumor activity in patients who had received previous tyrosine kinase inhibitors and immunotherapy.
Rechallenge with nivolumab after first-line immune checkpoint inhibition has moderate antitumor activity and acceptable tolerability.
Stereotactic radiotherapy for oligoprogressive tumors while on oral systemic therapy delays time to treatment switch.
A 14-mg starting dose of lenvatinib did not improve tolerability and had numerically worse efficacy than the approved 18-mg dose.
In a phase 2 trial, cabozantinib tolerably improved outcomes in patients pretreated with immunotherapy.
Page 1 of 2
Results 1 - 10 of 19

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
    Profession or Role
    Primary Specialty or Disease State